Working… Menu
Trial record 48 of 1547 for:    Androgens

Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02987829
Recruitment Status : Recruiting
First Posted : December 9, 2016
Last Update Posted : October 8, 2019
Janssen Pharmaceutica N.V., Belgium
Information provided by (Responsible Party):
Tracon Pharmaceuticals Inc.

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : March 2020
Estimated Study Completion Date : October 2020